Sciety and Sciety Venture Partners invest EUR 5.3 million in Capitainer
Sciety and Sciety Venture Partners recently completed an investment of EUR 5.3 million in Capitainer, a Swedish medtech company that has developed a unique platform for self-sampling of blood, facilitating remote healthcare solutions and personalized medicine. The capital will be used for sales & marketing and expanding production capacity to establish Capitainer as a leading supplier of self-sampling solutions with market-leading clinical accuracy.
Capitainer's platform allows people to collect blood samples from their fingertips, anytime and anywhere, and send the samples by regular mail to a laboratory for analysis. The company's innovative products are based on patented microfluidic technologies, delivering an exact sample volume essential for precise results. Capitainer's upcoming product, Capitainer®CF, will be one of a kind in the market, automatically extracting and metering plasma/serum from whole blood.
Since the first investment from Sciety and Sciety Venture Partners in 2020, Capitainer has made significant progress, launching new products and acquiring new customers. The company's commitment to innovation and its rapid growth have attracted the continued support of Sciety and Sciety Venture Partners, which is investing in Capitainer for the third time.
Andreas Lindblom, Managing Partner at Sciety, said, "We are excited to invest in Capitainer once again and support their vision of revolutionizing the way blood samples are collected. Their innovative platform has the potential to make a significant impact on personalized medicine and remote healthcare, improving the lives of people around the world."
Christopher Aulin, CEO at Capitainer, added, "This continued investment from Sciety and Sciety Venture Partners will enable us to accelerate our growth and expand our production capacity. We are confident that our unique self-sampling technology will become a game-changer in the healthcare industry, providing patients with greater convenience and accessibility while ensuring precise results."
The EUR 5.3 million investment from Sciety and Sciety Venture Partners will be used to ramp up production, launch new products and intensify sales & marketing activities, aiming to position Capitainer as a top choice for self-sampling solutions with the best clinical accuracy.
Contact
Andreas Lindblom, Managing Partner, Sciety: andreas.lindblom@sciety.se, phone 070-375 73 73.
Christopher Aulin, CEO, Capitainer: aulin@capitainer.se, phone 070-897 75 77.
About Capitainer
Capitainer AB is a Swedish medtech company founded in 2016. Capitainer develops and sells intelligent solutions for self-sampling of blood, plasma, and urine. The company has developed unique technologies for collecting an exact amount of fluid and then allowing it to dry. The sample card can be sent with regular mail to laboratories without needing refrigerated transports or special packaging. The precision and accuracy in Capitainer’s samples are market-leading and perform on the same level as established pipetting methods. The products can be applied within several market segments, for instance, clinical biomarkers, therapeutic drug monitoring, genomics, drug development, drug abuse and doping testing, and R&D and clinical studies.
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world.
